Organization to Assess Strategies for Ischemic Syndrome (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on preventing death, myocardial infarction, refractory angina and revascularization procedures in patients with acute myocardial ischemia without ST elevation: a randomized trial

Key Result

Recombinant hirudin reduced the risk of death, myocardial infarction, or refractory angina compared with heparin in patients with acute myocardial ischemia without ST elevation.

Key Points

• This study evaluates the effectiveness of recombinant hirudin versus heparin in preventing severe outcomes in patients with acute myocardial ischemia without ST elevation.
• Randomized trial comparing recombinant hirudin and heparin
• Target population includes patients with acute myocardial ischemia without ST elevation
• Primary outcomes include death, myocardial infarction, refractory angina, and need for revascularization procedures.
• Hirudin showed a significant reduction in death rates compared to heparin (HR not provided)
• Fewer patients experienced myocardial infarction in the hirudin group versus the heparin group (exact rates not specified)
• Revascularization procedures were less frequent with hirudin compared to heparin (rates not specified).